Literature DB >> 16455458

Transarterial chemoembolization with degradable starch microspheres, irinotecan, and mitomycin-C in patients with liver metastases.

Zenichi Morise1, Atsushi Sugioka, Ryoichi Kato, Junko Fujita, Sojun Hoshimoto, Takazumi Kato.   

Abstract

Degradable starch microspheres (DSMs) provide transient occlusion of small arteries and are thought to improve the therapeutic effect of anticancer drugs. Irinotecan (CPT-11) is one of the most effective anticancer agents. We herein report cases with liver metastases treated with transarterial chemoembolization with DSM, CPT-11, and mitomycin-C (DSM-CPT therapy). Five patients underwent DSM-CPT therapy for liver metastases that originated from colorectal cancer for four and gastric cancer for one. They all lack indication for surgery. They were all male with an age range of 42-78 years (mean, 55.2 years). Three of them had pretreatment histories with 5-fluorouracil or related agents, and four of them had combined systemic or local chemotherapy at the period. Required doses for stasis of whole blood flow of hepatic artery of DSMs were used with CPT-11 and mitomycin-C. After one to six injections, four patients had a partial response and the disease progressed in one patient with gastric cancer origin. Two of the partial response patients underwent surgery after 2 months of the partial response period. Carcinoembryonic antigen and CA19-9 levels in partial response patients decreased to 16.1% and 19.3% of the level before treatment, respectively. DSM-CPT therapy can be a potential therapy for liver metastases.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16455458     DOI: 10.1016/j.gassur.2005.08.004

Source DB:  PubMed          Journal:  J Gastrointest Surg        ISSN: 1091-255X            Impact factor:   3.452


  21 in total

1.  New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada.

Authors:  P Therasse; S G Arbuck; E A Eisenhauer; J Wanders; R S Kaplan; L Rubinstein; J Verweij; M Van Glabbeke; A T van Oosterom; M C Christian; S G Gwyther
Journal:  J Natl Cancer Inst       Date:  2000-02-02       Impact factor: 13.506

2.  Genetic predisposition to the metabolism of irinotecan (CPT-11). Role of uridine diphosphate glucuronosyltransferase isoform 1A1 in the glucuronidation of its active metabolite (SN-38) in human liver microsomes.

Authors:  L Iyer; C D King; P F Whitington; M D Green; S K Roy; T R Tephly; B L Coffman; M J Ratain
Journal:  J Clin Invest       Date:  1998-02-15       Impact factor: 14.808

3.  [Conversion of CPT-11 into SN-38 in human tissues].

Authors:  A Kono; Y Hara
Journal:  Gan To Kagaku Ryoho       Date:  1991-09

4.  Continuous infusion of hepatic arterial irinotecan in pretreated patients with colorectal cancer metastatic to the liver.

Authors:  J M G H van Riel; C J van Groeningen; J de Greve; G Gruia; H M Pinedo; G Giaccone
Journal:  Ann Oncol       Date:  2004-01       Impact factor: 32.976

5.  Randomised trial of irinotecan plus supportive care versus supportive care alone after fluorouracil failure for patients with metastatic colorectal cancer.

Authors:  D Cunningham; S Pyrhönen; R D James; C J Punt; T F Hickish; R Heikkila; T B Johannesen; H Starkhammar; C A Topham; L Awad; C Jacques; P Herait
Journal:  Lancet       Date:  1998-10-31       Impact factor: 79.321

6.  Randomised trial of irinotecan versus fluorouracil by continuous infusion after fluorouracil failure in patients with metastatic colorectal cancer.

Authors:  P Rougier; E Van Cutsem; E Bajetta; N Niederle; K Possinger; R Labianca; M Navarro; R Morant; H Bleiberg; J Wils; L Awad; P Herait; C Jacques
Journal:  Lancet       Date:  1998-10-31       Impact factor: 79.321

7.  Transient blood flow reduction induced by intra-arterial injection of degradable starch microspheres. Experiments on rats.

Authors:  J O Forsberg
Journal:  Acta Chir Scand       Date:  1978

8.  Effects of CPT-11 in combination with other anti-cancer agents in culture.

Authors:  Y Kano; K Suzuki; M Akutsu; K Suda; Y Inoue; M Yoshida; S Sakamoto; Y Miura
Journal:  Int J Cancer       Date:  1992-02-20       Impact factor: 7.396

Review 9.  Chemo-occlusion for the treatment of liver cancer. A new technique using degradable starch microspheres.

Authors:  T Taguchi
Journal:  Clin Pharmacokinet       Date:  1994-04       Impact factor: 6.447

10.  Intra-arterial infusion of doxorubicin with degradable starch microspheres. Improvement of hepatic tumor drug uptake.

Authors:  E R Sigurdson; J A Ridge; J M Daly
Journal:  Arch Surg       Date:  1986-11
View more
  4 in total

Review 1.  Recent advances in liver resection for hepatocellular carcinoma.

Authors:  Zenichi Morise; Norihiko Kawabe; Hirokazu Tomishige; Hidetoshi Nagata; Jin Kawase; Satoshi Arakawa; Rie Yoshida; Masashi Isetani
Journal:  Front Surg       Date:  2014-06-16

2.  Transarterial chemoembolization (TACE) using mitomycin and lipiodol with or without degradable starch microspheres for hepatocellular carcinoma: comparative study.

Authors:  Tatjana Gruber-Rouh; Cornelia Schmitt; Nagy N N Naguib; N A Nour-Eldin; Katrin Eichler; Martin Beeres; Thomas J Vogl
Journal:  BMC Cancer       Date:  2018-02-14       Impact factor: 4.430

Review 3.  [Update on chemoinfusion and chemoembolization treatments].

Authors:  A Lubienski; M Simon; K Lubienski; J Gellissen; R-T Hoffmann; T F Jakobs; T Helmberger
Journal:  Radiologe       Date:  2007-12       Impact factor: 0.803

4.  MRI visible drug eluting magnetic microspheres for transcatheter intra-arterial delivery to liver tumors.

Authors:  Dong-Hyun Kim; Jeane Chen; Reed A Omary; Andrew C Larson
Journal:  Theranostics       Date:  2015-02-07       Impact factor: 11.556

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.